Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer

Successful therapeutic options remain elusive for pancreatic cancer. The exquisite sensitivity and specificity of humoral and cellular immunity may provide therapeutic approaches if antigens specific for pancreatic cancer cells can be identified. Here we characterize SAS1B (ovastacin, ASTL, astacin-...

Descripción completa

Detalles Bibliográficos
Autores principales: Knapp, Kiley A., Pires, Eusebio S., Adair, Sara J., Mandal, Arabinda, Mills, Anne M., Olson, Walter C., Slingluff, Craig L., Parsons, J. Thomas, Bauer, Todd W., Bullock, Timothy N., Herr, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823626/
https://www.ncbi.nlm.nih.gov/pubmed/29507667
http://dx.doi.org/10.18632/oncotarget.23944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823626/
https://www.ncbi.nlm.nih.gov/pubmed/29507667
http://dx.doi.org/10.18632/oncotarget.23944

Ejemplares similares